Small cell lung cancer: circulating tumor cell lines and expression of mediators of angiogenesis and coagulation

Aim: Coagulation is frequently activated in cancer patients and has been correlated with an unfavorable prognosis. To evaluate whether a putative release of tissue factor (TF) by circulating tumor cells (CTCs) represents a target to impair the dissemination of small cell lung cancer (SCLC), the expression of relevant proteins in a panel of permanent SCLC and SCLC CTC cell lines that have been established at the Medical University of Vienna. Methods: Five CTC and SCLC lines were analyzed using a TF enzyme-linked immunosorbent assay (ELISA) tests, RNA sequencing, and western blot arrays covering 55 angiogenic mediators. Furthermore, the influence of topotecan and epirubicin as well as hypoxia-like conditions on the expression of these mediators was investigated. Results: The results demonstrate that the SCLC CTC cell lines express no significant amounts of active TF but thrombospondin-1 (TSP-1), urokinase-type plasminogen activator receptor (uPAR), vascular endothelial-derived growth factor (VEGF) and angiopoietin-2 in two cases. The major difference between the SCLC and SCLC CTC cell lines found was the loss of the expression of angiogenin in the blood-derived CTC lines. Topotecan and epirubicin decreased the expression of VEGF, whereas hypoxia-like conditions upregulated VEGF. Conclusions: Active TF capable of triggering coagulation seems not to be expressed in SCLC CTC cell lines in significant levels and, thus, CTC-derived TF seems dispensable for dissemination. Nevertheless, all CTC lines form large spheroids, termed tumorospheres, which may become trapped in clots of the microvasculature and extravasate in this supportive microenvironment. The contribution of clotting to the protection and dissemination of CTCs in SCLC may be different from other solid tumors such as breast cancer.

[1]  N. Mackman,et al.  Tissue factor and its procoagulant activity on cancer‐associated thromboembolism in pancreatic cancer: Comment by Mackman et al. , 2022, Cancer science.

[2]  G. Botti,et al.  Angiogenesis Inhibitors in Small Cell Lung Cancer , 2021, Frontiers in Oncology.

[3]  Chengping Hu,et al.  Do lung cancer patients require routine anticoagulation treatment? A meta-analysis , 2020, The Journal of international medical research.

[4]  L. Ek,et al.  Coagulation biomarkers and prediction of venous thromboembolism and survival in small cell lung cancer: A sub-study of RASTEN - A randomized trial with low molecular weight heparin , 2018, PloS one.

[5]  P. Metharom,et al.  Cancer-Associated Thrombosis: An Overview of Mechanisms, Risk Factors, and Treatment , 2018, Cancers.

[6]  R. Schiff,et al.  Perspective on Circulating Tumor Cell Clusters: Why It Takes a Village to Metastasize. , 2018, Cancer research.

[7]  D. Haber,et al.  A conduit to metastasis: circulating tumor cell biology , 2017, Genes & development.

[8]  R. Zeillinger,et al.  Small cell lung cancer: model of circulating tumor cell tumorospheres in chemoresistance , 2017, Scientific Reports.

[9]  A. Noël,et al.  Tissue Factor Induced by Epithelial-Mesenchymal Transition Triggers a Procoagulant State That Drives Metastasis of Circulating Tumor Cells. , 2016, Cancer research.

[10]  R. Zeillinger,et al.  Small cell lung cancer: Circulating tumor cells of extended stage patients express a mesenchymal-epithelial transition phenotype , 2016, Cell adhesion & migration.

[11]  B. Rath,et al.  Small cell lung cancer: Recruitment of macrophages by circulating tumor cells , 2016, Oncoimmunology.

[12]  A. Berns,et al.  Origins, genetic landscape, and emerging therapies of small cell lung cancer , 2015, Genes & development.

[13]  Sridhar Ramaswamy,et al.  Circulating Tumor Cell Clusters Are Oligoclonal Precursors of Breast Cancer Metastasis , 2014, Cell.

[14]  R. Muschel,et al.  Coagulation and metastasis: what does the experimental literature tell us? , 2013, British journal of haematology.

[15]  Chuan-Yuan Li,et al.  Effects of tumor microenviromental factors on VEGF expression. , 2013, Biomedical reports.

[16]  J. Bernaudin,et al.  Tissue factor over-expression by human pancreatic cancer cells BXPC3 is related to higher prothrombotic potential as compared to breast cancer cells MCF7. , 2012, Thrombosis research.

[17]  P. Reitsma,et al.  The relationship between tissue factor and cancer progression: insights from bench and bedside. , 2012, Blood.

[18]  R. Seitz,et al.  Inducible expression of tissue factor in small-cell lung cancer: impact on morphology and matrix metalloproteinase secretion , 2012, Journal of Cancer Research and Clinical Oncology.

[19]  M. Barcinski,et al.  Malignant transformation in melanocytes is associated with increased production of procoagulant microvesicles , 2011, Thrombosis and Haemostasis.

[20]  Massimo Cristofanilli,et al.  Molecular mechanisms of metastasis in breast cancer—clinical applications , 2010, Nature Reviews Clinical Oncology.

[21]  J. Rak,et al.  Tissue factor in tumour progression. , 2009, Best practice & research. Clinical haematology.

[22]  Y. Gruel,et al.  Tissue Factor Expression in Non-small Cell Lung Cancer: Relationship with Vascular Endothelial Growth Factor Expression, Microvascular Density, and K-ras Mutation , 2008, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[23]  L. Lacombe,et al.  Tissue factor expression correlates with disease‐specific survival in patients with node‐negative muscle‐invasive bladder cancer , 2007, International journal of cancer.

[24]  H. Büller,et al.  Cancer and thrombosis: from molecular mechanisms to clinical presentations , 2007, Journal of thrombosis and haemostasis : JTH.

[25]  S. Hirohashi,et al.  Prognostic Significance of Tissue Factor in Pancreatic Ductal Adenocarcinoma , 2005, Clinical Cancer Research.

[26]  M. Gasco,et al.  Prospective evaluation of major vascular events in patients with nonsmall cell lung carcinoma treated with cisplatin and gemcitabine , 2005, Cancer.

[27]  Marina Heiden,et al.  Tissue factor is the only activator of coagulation in cultured human lung cancer cells. , 2001, Lung cancer.

[28]  G. Tuszynski,et al.  Tumour cell thrombospondin-1 regulates tumour cell adhesion and invasion through the urokinase plasminogen activator receptor , 2000, British Journal of Cancer.

[29]  H. ten Cate,et al.  Factor IX is activated in vivo by the tissue factor mechanism. , 1990, Blood.

[30]  W. Kisiel,et al.  Abnormal regulation of coagulation/fibrinolysis in small cell carcinoma of the lung , 1990, Cancer.

[31]  V. Costa,et al.  The Multifaceted Role of Annexin A1 in Viral Infections , 2023, Cells.